Value in prostate cancer treatment
| Autor: | Robert R. Bahnson |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty Cost–benefit analysis business.industry Cancer General Medicine Disease 030204 cardiovascular system & hematology medicine.disease 03 medical and health sciences Prostate cancer 0302 clinical medicine Quality of life (healthcare) Procurement Internal medicine Health care medicine Surgery 030212 general & internal medicine business Intensive care medicine Value (mathematics) |
| Zdroj: | Journal of Surgical Oncology. 114:288-290 |
| ISSN: | 0022-4790 |
| DOI: | 10.1002/jso.24285 |
| Popis: | Value in health care is measured by outcomes and expense. An agreed upon desirable outcome can be indexed against the health care expenditure required for procurement. Prostate cancer treatment is an especially difficult subject for investigation of value. The late onset of the disease, coupled with competitive mortality risk, confounds value analysis. When cost considerations are made paramount, observation is the apparent treatment of choice. J. Surg. Oncol. 2016;114:288-290. © 2016 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text